Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000945068 | SCV001091054 | likely benign | Tuberous sclerosis 2 | 2024-05-15 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001655648 | SCV001870990 | likely benign | not provided | 2020-09-15 | criteria provided, single submitter | clinical testing | In silico analysis supports that this variant does not alter splicing; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV000945068 | SCV002041228 | benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV000945068 | SCV005407720 | benign | Tuberous sclerosis 2 | 2024-09-09 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is intronic and is not expected to impact mRNA splicing. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. |
Ambry Genetics | RCV004950087 | SCV005523410 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-09-19 | criteria provided, single submitter | clinical testing | The c.482-4C>T intronic variant results from a C to T substitution 4 nucleotides upstream from coding exon 5 in the TSC2 gene. This nucleotide position is poorly conserved in available vertebrate species. In silico splice site analysis for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |